Author: admin

Oleap Archer AI Headset Redefines Communication in the Age of AI

The audio technology landscape is constantly evolving, and Oleap is making a bold entry with its groundbreaking Archer AI Meeting Headset. Designed to tackle the challenges of modern communication, this device combines advanced AI capabilities with exceptional sound quality, offering users a tool that’s not just innovative but genuinely practical.

A Headset Built for the Modern World

The Oleap Archer isn’t just another gadget—it’s a solution. Whether you’re navigating the chaos of open-plan offices, managing back-to-back virtual meetings, or simply trying to capture important notes on the go, the Archer is engineered to streamline your communication.

At its core lies 50dB Environmental Noise Cancellation (ENC), a feature that sets a new standard for clarity. Traditional headsets often fall short in noisy environments, leaving users struggling to be heard over background chatter or ambient noise. The Archer changes that. By leveraging advanced algorithms and machine learning, it actively identifies and eliminates unwanted sounds in real time, ensuring your voice comes through loud and clear.

But it’s not just about noise cancellation. The AI-powered transcription and summarization capabilities of the Archer are where it truly shines. Supporting 89 languages with speaker identification, this headset doesn’t just record conversations—it transforms them into actionable insights. Imagine ending a meeting with a neatly summarized document highlighting key points, action items, and deadlines, all generated automatically. For professionals, students, and content creators, this is a game-changer.

Versatility for Every Scenario

The Archer isn’t limited to just one use case. With four distinct recording modes, it adapts to whatever you need:

1. Call Mode: Perfect for phone calls, ensuring crystal-clear audio for both parties.

2. Personal Mode: Ideal for recording voice memos or personal notes.

3. Media Mode: Designed for listening to music, podcasts, or other media.

4. Ambient Mode: Captures ambient sounds while still providing clear audio.

Whether you’re in a business meeting, brainstorming creative ideas, or simply capturing inspiration, the Archer adapts seamlessly to your needs.

Design Meets Comfort

Oleap hasn’t just focused on functionality—they’ve prioritized user experience. The semi-in-ear design ensures all-day comfort, making it ideal for long calls or extended use. The lightweight construction and ergonomic fit reduce fatigue, while the 270° rotatable boom microphone adds flexibility, allowing you to adjust the mic position for optimal sound capture.

With a battery life of up to 28 hours and a charging case that extends this further, you’ll never run out of power mid-meeting. And features like one-click mute and dual-device connection add convenience, letting you switch seamlessly between your smartphone and laptop without missing a beat.

Why the Archer Stands Out

In a crowded market dominated by brands like Jabra, Bose, and Sony, the Archer differentiates itself through its unique blend of features. While competitors offer noise cancellation and transcription tools, few match the Archer’s 50dB ENC or its multilingual AI capabilities.

“Traditional headsets are great for basic calls, but they don’t address the deeper needs of modern users,” said the CEO of Oleap. “We wanted to create a device that not only enhances sound quality but also becomes an active tool in your workflow. The Archer does exactly that.”

The Future of Audio Technology

As AI continues to reshape consumer electronics, devices like the Archer are leading the way. The integration of AI into everyday tools isn’t just a trend—it’s a necessity. Whether it’s noise cancellation, real-time translation, or intelligent summarization, AI is making communication more efficient and accessible.

The Archer also reflects a broader industry shift toward digital note-taking and content capture. In today’s fast-paced world, the ability to quickly capture and organize information is invaluable. By automating transcription and summarization, the Archer saves users time and ensures nothing important slips through the cracks.

Industry Trends and Market Positioning

The demand for reliable audio solutions is growing, especially as remote work and hybrid offices become the norm. According to recent studies, the global headset market is expected to reach $25 billion by 2027, driven by increasing adoption of remote communication tools.

Oleap is positioning the Archer as a premium solution for professionals and students who value efficiency and clarity. Its combination of advanced noise cancellation, AI-driven features, and user-friendly design positions it as a strong contender in this rapidly expanding market.

A Step Forward for Communication Technology

The Oleap Archer isn’t just a headset—it’s a reimagining of what audio technology can be. By combining cutting-edge AI, exceptional noise cancellation, and thoughtful design, it offers users a tool that enhances productivity and simplifies communication.

As AI continues to transform how we interact with technology, devices like the Archer will play a crucial role in shaping the future. Whether you’re managing a global team, capturing lecture notes, or creating content, the Archer provides a solution that’s both innovative and practical.

For anyone seeking clarity, efficiency, and reliability in their audio experience, the Oleap Archer is more than a gadget—it’s a transformation.

For more information, visit their official website here.

Media Contact
Company Name: Oleap
Contact Person: Jensen Chen
Email: Send Email
Country: China
Website: https://www.oleapai.com/

Federation of Catholic Teachers Secures First-Ever Contract for Teachers’ Aides and Assistants


Photo Courtesy: Federation of Catholic Teachers

New York, NY – June 23, 2025 – The Federation of Catholic Teachers (FCT) is proud to announce a groundbreaking achievement: the successful negotiation of the first Collective Bargaining Agreement (CBA) for approximately 800 Teachers’ Aides and Assistants across elementary schools in the Archdiocese of New York. This historic contract ensures critical improvements in wages, job security, benefits, and leave for a vital group of school employees who assist in supporting students and educators on a daily basis.

The new contract will provide significant gains for the teachers’ aides and assistants, strengthening their role within the school community. With this agreement, FCT continues to underscore its commitment to fair labor practices and worker protection for all employees within the education sector.

Key Contract Highlights

  • Job Security & Grievance Rights

The agreement introduces a formal grievance process to address cases of unjust discipline or contract violations. In addition, annual employment agreements will replace the previous informal letters of intent. The contract ensures job protection for employees affected by school downsizing or closures through a structured rehiring process and establishes clear protocols for performance evaluation and improvement.

  • Workplace Protections & Fair Pay

Teachers’ aides and assistants will now enjoy guaranteed, duty-free lunch breaks, along with compensation for attending school functions outside of their regular work hours. The contract also ensures fair pay when aides are required to cover lead teacher responsibilities or substitute in other classrooms.

  • Paid & Protected Leave

The new contract guarantees paid sick leave, along with paid leave for child-related illness, occupational injuries, and bereavement. Job-protected leave will also be available for maternity, adoption, and family medical emergencies.

  • Access to Benefits

Aides and assistants working 30 or more hours per week will have access to health insurance. Additionally, they will be able to participate in the Archdiocese’s 403(b) retirement plan and pension plan. Employees will also benefit from up to $500 per year in tuition assistance for their children attending ACS schools.

  • Compensation Increases & Bonuses

A 2% wage increase, effective September 1, 2025, will result in an estimated $400+ annual raise for many aides and assistants. Additionally, a one-time ratification bonus of $200 will be provided for full-time employees, and $100 for part-time employees.

Total Estimated Value: The contract will add over $5 million in new salary and benefits over its term.

A Historic Milestone in Representation

This contract is the first time that teachers’ aides and assistants in the Archdiocese have secured formal labor protections and benefits on such a large scale. These gains were achieved without the collection of dues, highlighting the Federation’s unwavering commitment to these essential school employees. A ratification vote will take place in the coming weeks and will be administered by an independent election agency. Voting instructions will be provided by mail, email, and text.

“This contract brings long-overdue recognition and protections to the teachers’ aides and assistants who play a vital role in our schools,” said Teresa Clarke, Vice President of the FCT.

About the Federation of Catholic Teachers (FCT):

The Federation of Catholic Teachers (FCT) represents educators, aides, and assistants across schools in the Archdiocese of New York. FCT advocates for fair labor practices, quality education, and workplace protections for all education professionals. Through collective bargaining, the FCT continues to ensure that members are supported and protected in their roles within the educational system.

Media Contact
Company Name: Federation of Catholic Teachers
Contact Person: Leanne Cole, President of the FCT
Email: Send Email
Phone: (718) 370-0081
Country: United States
Website: http://fct153.org

TOZO Unveils Exclusive Prime Day Deals on Innovative Audio Products

TOZO, the popular global audio brand known for fusing cutting-edge technology with sleek design, is rolling out limited-time Amazon Prime Day deals on some of its best-selling wireless audio products. During the Prime Day sale, Prime members can score up to 50% off TOZO’s top-rated audio gear.

“Our goal has always been to deliver high-quality audio experiences at accessible prices,” said Komi Zhang, Marketing Director at TOZO. “Prime Day gives us the perfect opportunity to introduce more users to our flagship products—and help them upgrade their everyday listening.”

Prime Day this year will be held from July 8 to July 11, extending to four days. Amazon’s 2025 Prime Day event will officially kick off on July 8 at 12:01 a.m. PDT and continue until midnight on July 11, providing Prime members with 96 hours of deals.

Featured TOZO Prime Day Deals:

1. TOZO Golden X1: The TOZO Golden X1 utilizes a combination of a 12mm dynamic driver and a customized Knowles balanced armature driver, delivering a Hi-Fi-level listening experience with an ultra-wide frequency response range of 12Hz to 44.1kHz that far exceeds your hearing range. It also supports LDAC high-definition audio decoding and has obtained Hi-Res Audio certification.

2. TOZO HT2: Immerse yourself in an extraordinary audio adventure with pristine sound quality in any environment. Seamlessly stay connected with crystal-clear calls every time. The 40mm Dynamic Driver Units provide an immersive sound experience, complemented by Hi-Res Audio Certification for audio quality that exceeds expectations.

3. TOZO Open EarRing: Experience all-day comfort with TOZO Open EarRing, designed for effortless listening. The innovative earring design sits gently outside your ear, providing a secure fit that lasts through your busiest days. Weighing just 5.6g, these feather-light yet durable headphones deliver captivating sound, featuring deep bass and crystal-clear highs. With a powerful 40-hour battery, you can enjoy uninterrupted music from morning to night. The smart LED display on the charging case keeps you updated, and the adaptive design lets you stay aware of your surroundings whether you’re working, exercising, or on the move.

These deals and others will be available through the TOZO website and the TOZO Amazon Store.

About TOZO

TOZO is an intelligent electronics brand owned by TOZO Inc., based in Seattle, USA. The TOZO brand was registered and established in 2015, adhering to the concept of “Tech Around You” and is committed to providing people with the latest technology in intelligent wearable products.

TOZO is committed to researching, developing, and manufacturing high-tech digital products, which include wireless audio, smart IoT, virtual reality, and digital accessories. TOZO is powered by an energetic R&D team and the world’s top factories. It is dedicated to producing the highest quality products by selecting environmentally friendly and high-quality materials, reducing intermediary steps, and improving efficiency. Our clients can expect excellent products, exceptional user experiences, and a greener life.

Media Contact
Company Name: TOZO
Contact Person: Alan Lee
Email: Send Email
Country: United States
Website: https://www.tozostore.com/

Janet H. Ethington Champions Workplace Kindness and Mental Health Awareness

Janet H. Ethington Champions Workplace Kindness and Mental Health Awareness

Janet H Ethington
Riverton HR Leader Encourages Everyday Acts of Compassion to Support Employee Wellbeing

RIVERTON, UT – June 23, 2025 – Janet H. Ethington, a veteran Human Resources Manager and community volunteer based in Riverton, Utah, is calling for a renewed focus on kindness and mental health in the workplace, encouraging individuals to take simple but meaningful actions in their daily lives to support others.

The initiative follows her widely circulated interview, “Leading with Heart: An Interview with Janet H. Ethington”, in which she shares lessons from a decades-long career in HR, as well as her experiences supporting employees through conflict, change, and burnout.

“Kindness is never wasted. Whether it’s a conversation with someone who’s struggling or simply showing respect in a tough moment, how we treat people sticks with them,” Ethington said. “It doesn’t take much to make someone feel seen and valued.”

The Silent Strain on Employee Wellbeing

According to a 2023 Gallup survey, 44% of employees worldwide report experiencing stress during much of the previous day. In the U.S., over 70% of workers say their mental health has affected their work performance at some point. Despite growing awareness, many employees—especially in high-pressure industries—still suffer in silence.

“Workplaces are made up of human beings. Life doesn’t stop when people walk through the office door,” Ethington noted. “We need to be more comfortable asking, ‘How are you, really?’ and giving people space to answer honestly.”

Listening, Leading, and Lifting

During her interview, Ethington recalled how small changes—like monthly check-ins, open-door policies, or mentorship programmes—had a tangible impact on retention and morale in one company facing high turnover.

“Sometimes, people just need to feel like someone’s in their corner,” she said. “You don’t need a big title or budget to offer that.”

Ethington’s perspective draws from years of experience not only in HR across industries, but also through her community work in Riverton, where she volunteers with local schools, food drives, and mentoring programmes.

“We get so caught up in performance and metrics, we forget that encouragement is a form of leadership too,” she added.

A Call to Action: Be the Reason Someone Feels Valued

Janet H. Ethington is urging individuals—not just managers or executives—to start making a difference in their own environments. She advocates for:

  • Asking genuine questions instead of routine “how are yous.”

  • Creating check-in habits with colleagues and friends.

  • Taking small breaks to reset rather than pushing through stress.

  • Volunteering to help others outside of work, which studies show can improve personal wellbeing.

  • Leading with patience, especially when someone is not at their best.

“I tell young professionals all the time: listen more than you speak. That alone can shift a team dynamic,” Ethington said. “Compassion is a skill. The more we practice it, the stronger our workplaces become.”

Moving Forward, Together

As part of her ongoing efforts, Ethington is encouraging others to join or start “Kindness in Action” days—monthly, informal initiatives where teams do something simple but meaningful: thank-you notes, coffee chats, or quick mental health breaks together.

“Even if it’s just one act of kindness a week, that ripple can grow,” she said. “You never know what someone’s carrying. You could be the moment their day turns around.”

For more information or to start your own workplace kindness initiative, Janet encourages individuals to reflect, act, and inspire others to do the same. Change begins with one person willing to care.

Contact: janetethington@emaildn.com

Media Contact
Contact Person: Janet H Ethington
Email: Send Email
Country: United States
Website: https://www.janetethingtonhr.com/

Dr David Banach Urges Public to Prioritise Infection Prevention and Health Literacy

Dr David Banach Urges Public to Prioritise Infection Prevention and Health Literacy

David Banach
“We Can’t See Infection Control Working—Until It Fails,” Says Longtime Physician and Educator

Connecticut, USA – In the wake of rising antibiotic resistance, persistent public health threats, and growing misinformation around disease prevention, Dr David Banach is calling on individuals and communities to take infection prevention seriously—before the next crisis emerges. A physician with nearly two decades of experience in infectious diseases and epidemiology, Dr Banach recently shared his concerns and insights in the interview “Fighting Infections, Teaching Tomorrow.”

“People often think infection prevention starts when there’s a problem,” Dr Banach noted. “But in reality, it starts long before—through habits and systems we build into everyday life.”

As a clinician, researcher, and public health leader, Dr Banach sees the effects of gaps in prevention daily. From hospital-acquired infections to community spread of viruses like RSV and influenza, many cases are preventable through consistent, science-based practices.

A Silent Threat: The High Cost of Poor Prevention

According to the Centers for Disease Control and Prevention (CDC), at least 2.8 million people in the U.S. contract antibiotic-resistant infections each year, resulting in over 35,000 deaths. In hospitals alone, one in 31 patients will experience a healthcare-associated infection on any given day.

Dr Banach believes much of this could be avoided by reinforcing what he calls “invisible safeguards.”

“The best infection control systems are ones people rarely notice—because they’re quietly preventing harm. It’s when those systems are weak or ignored that we see outbreaks,” he said.

He pointed to proper hand hygiene, sanitation protocols, and early diagnosis as powerful yet often overlooked tools. “They’re not glamorous, but they save lives.”

The Public’s Role: Prevention Starts at Home

Rather than putting the burden solely on healthcare systems, Dr Banach emphasises that every individual has a role in protecting themselves and others.

“This isn’t just a hospital issue. Washing hands, staying home when you’re sick, completing antibiotic prescriptions—these things matter more than most people realise.”

He encourages people to stay informed, ask questions at medical appointments, and advocate for health literacy in their communities. “If you don’t know why something is being done—ask. Education is a cornerstone of prevention.”

Education as a Long-Term Strategy

Dr Banach, who has taught for years in both clinical and classroom settings, says that preparing the next generation of healthcare professionals is one of his most fulfilling responsibilities.

“Teaching forces me to stay sharp, but it also gives me hope. These students will be the ones responding to future health threats. If we equip them to think critically and act early, we’re in better shape as a society.”

He also works closely with volunteer-run clinics, especially in underserved populations, where education and access often fall short.

A Call to Action: Build Stronger Habits, Stronger Communities

In reflecting on his career, Dr Banach believes the most impactful changes start with simple, consistent behaviour.

He encourages the public to:

  • Practice regular hand hygiene.

  • Avoid unnecessary antibiotics—and always finish prescribed ones.

  • Stay up to date on vaccinations.

  • Talk to healthcare providers about infection risks and prevention.

  • Support public health efforts at local and state levels.

“We don’t need to wait for another pandemic to take action,” he said. “The quiet, everyday choices we make can prevent the loud emergencies we hope to avoid.”

About Dr David Banach:

Dr David Banach is a physician specialising in infectious diseases and internal medicine. He teaches, conducts research in healthcare epidemiology, and volunteers at clinics serving vulnerable populations. A lifelong Connecticut resident, he has served on multiple health advisory committees and remains a vocal advocate for prevention-first healthcare approaches.

Media Contact:

Email: davidbanach@emaildn.com

Read the full interview: “Fighting Infections, Teaching Tomorrow”

Learn more about how you can take small steps to protect your health and community.

Media Contact
Contact Person: David Banach
Email: Send Email
Country: United States
Website: https://www.davidbanachwoodbridge.com/

Involved in a Cyber Attack? Here are UAE’s Best Lawyers in Cybercrimes

With the advancement of the world wide web, and the advent of social media, people have become increasingly comfortable in broadcasting their thoughts and personal information to the public online. People fail to realize the true impact or consequences of their actions. As a result, individuals often find themselves either as victims of cyber crimes or in breach of cyber laws.

The UAE has a strict set of laws to curb cybercrime and protect vulnerable individuals. These laws are enshrined under the Federal Decree Law No. 34 of 2021 on Combatting Rumors and Cybercrimes and other similar laws. If someone finds themselves to be in breach of UAE laws, due to social media content posted online, or if they find themselves as victims of cybercrime, it is extremely important that they choose the right legal representation in order to protect themselves. We have listed the top lawyers in the UAE who are experts in cyber laws.

1. Dr. Hassan Elhais

With almost 20 years’ experience in UAE Law, Dr. Hassan Elhais has keenly studied the evolution of laws regarding internet and the online world. His expertise is evident in the various articles he has written on the subject for newspapers and online magazines. He has also dealt with numerous cases involving cyberlaws, including online privacy breaches, data protection, problematic social media content and many more.

Due to the nature of internet related crimes, it is important that a Dubai Lawyer is familiar with the criminal law in UAE, and the legal system in the country. Dr. Hassan has been working closely with the judicial system and the Dubai courts for decades and is able expertly navigate the legal system here. It is for this reason that he has been declared as the best lawyer in Dubai, by his clients.

Contact Person: Dr Hassan Elhais

Email: Send Email

Phone: +971 4 355 8000

Country: United Arab Emirates

Website: www.professionallawyer.me

2. Awatif Mohammad Shoqi Advocates and Legal Consultancy

Awatif Mohammad Shoqi Advocates and Legal Consultancy was previously known as Al Rowaad Advocates and Legal consultants. This UAE Law firm has extensive experience in the UAE criminal Law, particularly cybercrimes and financial crimes carried out over the internet. The firm comprises of top UAE lawyers and cybercrime experts. Awatif has handled numerous cybercrime matters including data breaches, cases relating to dubious online transactions, internet defamation, and cyber security.

3. Mohammad Najjar

Mohammad Najjar is a top UAE lawyer involved in criminal matters and helps in cases related to cybercrimes. He has a large team that efficiently handles criminal matters from end to end.

4. Diane Hamade

Diane Hamade’s expatriate clientele depends on her expertise in all legal matters including criminal law. She offers legal support for individuals facing criminal charges, ensuring fair representation at every stage of the legal process.

Cybercrime can no longer be classified as a niche field. It has now become an essential aspect of the legal system, particularly, under Criminal law. Lawyers involved in cyber laws not only help in protecting vulnerable groups such as the senior citizens, woman and children, but also help in spreading knowledge by offering legal advice on the matter. Although the UAE has some of the most efficient lawyers in the field of cyberlaws and cybercrimes, Dr. Hassan emerges as the best UAE lawyer as per various online legal platforms.

Media Contact
Company Name: IndNewsWire
Contact Person: Sales Team
Email: Send Email
Country: India
Website: https://indnewswire.com/

Bronchiectasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Companies by DelveInsight

“Bronchiectasis Treatment Market”
Bronchiectasis Companies are Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others.

(Albany, USA) DelveInsight’s “Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of bronchiectasis, historical and forecasted epidemiology, as well as the bronchiectasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The latest healthcare forecast report provides an in-depth analysis of Bronchiectasis, offering comprehensive insights into the Bronchiectasis revenue trends, prevalence, and treatment landscape. The report delves into key Antiphospholipid Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Bronchiectasis therapies. Additionally, we cover the landscape of Bronchiectasis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Bronchiectasis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Bronchiectasis space.

 

Discover Key Insights into the Bronchiectasis Market with DelveInsight’s In-Depth Report @ Bronchiectasis Market Size

 

Key Takeaways from the Bronchiectasis Market Report

  • Bronchiectasis Market Size in the 7MM was ~USD 1,581.2 million in 2023, estimated DelveInsight
  • In November 2024:- Sanofi-A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis. ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
  • In November 2024:- Boehringer Ingelheim- This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term.
  • In November 2024:- Verona Pharma PLC- This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
  • According to DelveInsight’s epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques.
  • In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.
  • Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases.
  • Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases.
  • Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males.
  • In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to other pathogen, accounting for 46,600 cases.
  • In 2023, among the 7MM, Japan had approximately 96,580 diagnosed prevalent cases of NCFB.
  • In 2023, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of cystic fibrosis bronchiectasis, with approximately 41,566 cases, while Japan accounted for the least, with only 59 cases.
  • Among the gender-specific cases of cystic fibrosis bronchiectasis in EU4 and the UK in 2023, there were approximately 17,081 cases for females and around 18,738 cases for males.
  • Among the age-specific cases of cystic fibrosis bronchiectasis in Japan in 2023, there were approximately 24 cases for children and around 36 cases for adult.
  • In 2023, the majority of etiology-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in Japan were attributed to Staphylococcus aureus, accounting for 36 cases.
  • The leading Bronchiectasis Companies such as Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others.
  • Promising Bronchiectasis Therapies such as CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others.

 

Stay ahead in the Bronchiectasis Therapeutics Market with DelveInsight’s Strategic Report @ Bronchiectasis Market Outlook

 

Bronchiectasis Epidemiology Segmentation in the 7MM

  • Total diagnosed prevalent cases
  • Gender-specific diagnosed prevalent cases
  • Severity-specific diagnosed prevalent cases
  • Etiology-specific diagnosed prevalent cases
  • Microbiology of NCFB patients,
  • Total diagnosed prevalent cases
  • Gender-specific diagnosed prevalent cases
  • Age-specific diagnosed prevalent cases
  • Microbiology of cystic fibrosis bronchiectasis

 

Download the report to understand which factors are driving Bronchiectasis epidemiology trends @ Bronchiectasis Prevalence

 

Bronchiectasis Emerging Drugs

  • Brensocatib: Insmed/AstraZeneca

Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with bronchiectasis, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024. If approved, brensocatib is expected to launch in the US by mid-2025, followed by launches in Europe and Japan in the first half of 2026. In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with bronchiectasis at the CHEST 2024 Annual Meeting. Furthermore, the EMA approved a Pediatric Investigational Plan for brensocatib in bronchiectasis patients, and brensocatib has gained access to the PRIME scheme and Breakthrough Therapy Designation for adult bronchiectasis patients.

 

  • Inhaled Colistimethate Sodium (CMS I-neb): Zambon

CMS I-neb is an investigational inhaled therapy for adults with bronchiectasis colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa. In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal. The Phase III PROMIS-I trial demonstrated a significant reduction in pulmonary exacerbation rates. Although the PROMIS-II trial was terminated early due to the pandemic, pre-pandemic data showed consistency with PROMIS-I outcomes. Zambon is working with regulatory authorities to expedite patient access. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), as well as QIDP and Fast Track Designation (FTD).

 

  • FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with NCFB associated with eosinophilic inflammation (bronchiectasis + EI). According to clinicaltrials.gov, FASENRA completed Phase III clinical trials for this indication in April 2024.

 

Bronchiectasis Treatment Market

The treatment of bronchiectasis involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation, such as DPP1 inhibitors, represent innovative approaches. Together, these drug classes form a comprehensive yet evolving treatment landscape for bronchiectasis, addressing its multifaceted pathophysiology.

 

Get In-Depth Knowledge on Bronchiectasis Market Trends and Forecasts with DelveInsight @ Bronchiectasis Treatment Market

 

Bronchiectasis Market Outlook

The market for bronchiectasis is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of treatment options which includes medications, chest physical therapy, hydration, and in severe cases, oxygen therapy with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies, such as Brensocatib, a Dipeptidyl Peptidase 1 (DPP1) inhibitor, and BI 1291583, a cathepsin C inhibitor, target neutrophilic inflammation through distinct mechanisms, thereby offering novel approaches to improve patient outcomes.

 

Bronchiectasis Therapeutics Market

Additionally, investigational therapies like CMS I-neb and monoclonal antibodies such as FASENRA and Itepekimab present further options by directly targeting specific inflammatory pathways associated with eosinophilic inflammation. The incorporation of non-pharmacological approaches, particularly Airway Clearance Techniques (ACTs), complements pharmacological regimens, enhancing mucus clearance and preventing infection. However, the market faces challenges, including a lack of consensus guidelines and under-researched therapies like mucolytics and hyperosmolar agents, which may hinder optimal patient management.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Bronchiectasis Market Report @ Bronchiectasis Market Drivers and Barriers

 

Scope of the Bronchiectasis Market Report

  • Coverage- 7MM
  • Bronchiectasis Companies- Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others.
  • Bronchiectasis Therapies- CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others.
  • Bronchiectasis Therapeutic Assessment: Bronchiectasis Current marketed and Lipodystrophy Emerging Therapies
  • Bronchiectasis Market Dynamics: Bronchiectasis Market drivers and Bronchiectasis Market Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Emerging Drugs

11. Bronchiectasis: Market Analysis

12. Key Opinion Leaders’ Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchiectasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Companies by DelveInsight

Antiphospholipid Syndrome Drugs Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Epidemiology, Therapies, Companies by DelveInsight

“Antiphospholipid Syndrome Drugs Market”
Antiphospholipid Syndrome Companies included are Novartis AG, Fresenius Kabi AG, Akorn Incorporated, Teva Pharmaceutical Industries Ltd, Mylan N.V, Johnsons & Johnsons Pvt Ltd, F. Hoffman-La Roche Ltd., Lilly, Merck & Co., Inc., Aurobindo Pharma, Shenzhen Techdow Pharmaceutical Co., Ltd, Bayer AG, AstraZeneca, and several others.

(Albany, USA) DelveInsight’s “Antiphospholipid Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antiphospholipid Syndrome, historical and forecasted epidemiology as well as the Antiphospholipid Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Antiphospholipid Syndrome, offering comprehensive insights into the Antiphospholipid Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Antiphospholipid Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Antiphospholipid Syndrome therapies. Additionally, we cover the landscape of Antiphospholipid Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Antiphospholipid Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Antiphospholipid Syndrome space.

Antiphospholipid Syndrome Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. The detailed market research, industry sector growth and development, and new product introductions covered in this report on the Antiphospholipid Syndrome Market are of great assistance to the important new commercial players joining the market.

 

Explore the intricate details of the Antiphospholipid Syndrome Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Antiphospholipid Syndrome Market Forecast. Click here to stay ahead in healthcare innovation @ Antiphospholipid Syndrome Market Size

 

Key takeaways from Antiphospholipid Syndrome Market Report

  • Antiphospholipid Syndrome Market Companies included Novartis AG, Fresenius Kabi AG, Akorn Incorporated, Teva Pharmaceutical Industries Ltd, Mylan N.V, Johnsons & Johnsons Pvt Ltd, F. Hoffman-La Roche Ltd., Lilly, Merck & Co., Inc., Aurobindo Pharma, Shenzhen Techdow Pharmaceutical Co., Ltd, Bayer AG, AstraZeneca, and several others.
  • Antiphospholipid Syndrome Market Therapies included RAY121, Rituximab, CoaguChek XS, Standard Lab Draw, Apixaban, Warfarinm, Rivaroxaban, and several others.
  • According to a study conducted by García et. al. (2019), the annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42-58) per 100,000 population.
  • According to a study by D’Cruz et. al. (2019), prevalence in the UK peaked at 50 (95% CI 49 – 55) in females in 2011 and 9.8 (95% CI 8.6 – 11.1) per 100,000 in males in 2012.
  • According to a study by Radin et. al. (2020), the prevalence cases of Antiphospholipid antibody syndrome in Italy are 40-50 cases per 100,000 persons and the diagnosis rate of Antiphospholipid antibody syndrome in Italy were 63% in aged of ≤50 years, 39% ≤40 years, and 18% ≤30 years.
  • In April 2025, Biologic Therapy Significantly Improves Pregnancy Outcomes in Women with Antiphospholipid Syndrome at High Risk for Serious Complications According to Hospital for Special Surgery.
  • In January 2025, Werfen received FDA 510(k) clearance for its Aptiva® APS IgG and IgM Reagents. Using particle-based multi-analyte technology (PMAT), these assays help diagnose primary and secondary APS by measuring anti-cardiolipin and anti-beta 2 glycoprotein 1 in human serum.
  • In December 2024, Chugai Pharmaceutical announced results of a Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

 

Navigate the complexities of the Antiphospholipid Syndrome Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Antiphospholipid Syndrome Market Forecast. Click here to get more insights @ Antiphospholipid Syndrome Treatment Market

 

Antiphospholipid Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

 

Antiphospholipid Syndrome Epidemiology Insights

According to American College of Rheumatology (2021) it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men. For arterial events, recurrences are also prevented with drugs that inhibit platelets, such as aspirin and clopidogrel (Plavix) and for pregnancy related events subcutaneous injections of heparin and low-dose aspirin are the standard therapy for preventing miscarriages.

  • Total Antiphospholipid Syndrome Prevalence Case
  • Antiphospholipid Syndrome Age-specific Cases
  • Antiphospholipid Syndrome Clinical Manifestations
  • Antiphospholipid Syndrome Gender-specific Cases
  • Antiphospholipid Syndrome Diagnosed and Treatable Cases

 

Delve deep into the Antiphospholipid Syndrome Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Antiphospholipid Syndrome Market Forecast. Click here to shape the future @ Antiphospholipid Syndrome Prevalence

 

Antiphospholipid Syndrome Treatment Market

Currently, treatment of patients with Antiphospholipid syndrome is based on long-term oral anticoagulation therapy for thrombotic manifestations and the combination of low dose aspirin (LDA) and low-molecular-weight heparin (LMWH) to prevent obstetric manifestations. However, the lack of well-designed studies means that the strength of some recommendations is debatable. Innovative therapeutic approaches, such as immune modulation, complement inhibition, and targeting inflammation, are under study. Further mechanistic and clinical studies are needed to develop improved therapies for this potentially devastating illness.

 

Antiphospholipid Syndrome Market Insights

Low dose aspirin (LDA) and Low-molecular-weight heparin (LMWH) used in thrombotic Antiphospholipid syndrome women. Sometime LMWH is used with or without aspirin throughout pregnancy. LMWH acts through mechanisms alternative to its well-known anticoagulant effect, because of its ability to bind β2GPI. For those patients with purely obstetric APS and no prior thrombosis (OAPS), prophylactic dose LMWH and LDA until 6 weeks postpartum is recommended.

 

Unlock insights into the Antiphospholipid Syndrome Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Antiphospholipid Syndrome Market Forecast. Click here @ Antiphospholipid Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

 

Antiphospholipid Syndrome Market Forecast

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

 

Antiphospholipid Syndrome Market Drivers

  • Increase in awareness
  • Increase in R&D of diagnostic tools leads to better diagnosis of the disease
  • Increasing Prevalence of the Disease

 

Antiphospholipid Syndrome Market Barriers

  • Off-label drugs usage
  • Lack of emerging therapies
  • Lack of management of Disease

 

Gain a strategic edge in the Antiphospholipid Syndrome Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Antiphospholipid Syndrome Market Forecast. Click here to lead in advancements @ Antiphospholipid Syndrome Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis for Antiphospholipid Syndrome

4. Antiphospholipid Syndrome Market Overview at a Glance

5. Antiphospholipid Syndrome Disease Background and Overview

6. Patient Journey

7. Antiphospholipid Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Antiphospholipid Syndrome Unmet Needs

10. Key Endpoints of Antiphospholipid Syndrome Treatment

11. Antiphospholipid Syndrome Marketed Products

12. Antiphospholipid Syndrome Emerging Therapies

13. Antiphospholipid Syndrome Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Antiphospholipid Syndrome Market Outlook

16. Access and Reimbursement Overview of Antiphospholipid Syndrome

17. KOL Views

18. Antiphospholipid Syndrome Market Drivers

19. Antiphospholipid Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Antiphospholipid Syndrome Drugs Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Epidemiology, Therapies, Companies by DelveInsight

Alopecia Areata Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight

“Alopecia Areata Drugs Market”
Alopecia Areata companies are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, and others.

(Albany, USA) DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The market report on Alopecia Areata presents up-to-date information on treatment approaches, emerging medications, the market share of different therapies, and the current as well as projected Alopecia Areata market size from 2020 to 2034, across seven major markets. The report includes details on the prevailing treatment practices and guidelines for Alopecia Areata, along with an analysis of market drivers, barriers, and unmet medical needs. This comprehensive assessment aims to identify the most promising opportunities and evaluate the overall potential of the Alopecia Areata market.

 

Request for a Free Sample Report @ Alopecia Areata Market Forecast

 

Some facts of the Alopecia Areata Market Report are:

  • According to DelveInsight, Alopecia Areata Market is expected to grow at a CAGR of ~27% by 2034.
  • According to DelveInsight’s patient-based forecasting model, the total market size of Alopecia Areata in the 7MM was around USD 180 million in 2023.
  • Leading Alopecia Areata companies working in the market are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others
  • Key Alopecia Areata Therapies expected to launch in the market are Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others.
  • The increasing R&D investments for strong Alopecia Areata pipeline candidates by prominent players such as Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, and others will contribute positively to the Alopecia Areata treatment landscape in the forthcoming years.

 

Alopecia Areata Overview

Alopecia areata is an autoimmune disorder that results in sudden hair loss. It occurs when the immune system mistakenly targets hair follicles, causing them to shrink and enter a dormant phase. This leads to hair thinning or complete hair loss in round or oval patches on the scalp or other parts of the body.

The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic and environmental factors. It can affect individuals of any age, gender, or ethnic background.

While alopecia areata is generally not a life-threatening condition, it can have a significant psychological and emotional impact on those affected. The unpredictable nature of hair loss and its potential for recurrence can cause distress and self-esteem issues.

There is currently no known cure for alopecia areata, but various treatment options aim to stimulate hair regrowth and manage the condition. These may include topical corticosteroids, topical immunotherapy, oral medications, and injectable medications. Hairpieces, wigs, or cosmetic camouflage techniques can also be utilized to cover areas of hair loss.

 

Learn more about Alopecia Areata treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Alopecia Areata Treatment Market

 

Alopecia Areata Market

The Alopecia Areata market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alopecia Areata market trends by analyzing the impact of current Alopecia Areata therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia Areata market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alopecia Areata market in 7MM is expected to witness a major change in the study period 2020-2034.

 

Alopecia Areata Epidemiology

The Alopecia Areata epidemiology section provides insights into the historical and current Alopecia Areata patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alopecia Areata market report also provides the diagnosed patient pool, trends, and assumptions.

 

Explore more about Alopecia Areata Epidemiology @ Alopecia Areata Market Dynamics and Trends

 

Alopecia Areata Drugs Uptake

This section focuses on the uptake rate of the potential Alopecia Areata drugs recently launched in the Alopecia Areata market or expected to be launched in 2020-2034. The analysis covers the Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.

Alopecia Areata Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alopecia Areata market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Alopecia Areata Pipeline Development Activities

The Alopecia Areata report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key Alopecia Areata companies involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Alopecia Areata pipeline development activities @ https://www.delveinsight.com/report-store/alopecia-areata-market

 

Alopecia Areata Therapeutics Assessment

Major key companies are working proactively in the Alopecia Areata Therapeutics market to develop novel therapies which will drive the Alopecia Areata treatment markets in the upcoming years are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others.

 

Scope of the Alopecia Areata Market Report:

  • Coverage: 7MM
  • Study Period: 2020-2034
  • Alopecia Areata Companies: Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare, Arena Pharmaceuticals, LEO Pharma, Aclaris Therapeutics, Bristol-Myers Squibb, Novartis, and many others.
  • Alopecia Areata Drugs: Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others.

 

Learn more about the emerging Alopecia Areata therapies & key companies @ Alopecia Areata Clinical Trials and FDA Approvals

 

Alopecia Areata Report Key Insights

1. Alopecia Areata Patient Population

2. Alopecia Areata Market Size and Trends

3. Key Cross Competition in the Alopecia Areata Market

4. Alopecia Areata Market Dynamics (Key Drivers and Barriers)

5. Alopecia Areata Market Opportunities

6. Alopecia Areata Therapeutic Approaches

7. Alopecia Areata Pipeline Analysis

8. Alopecia Areata Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Alopecia Areata Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Alopecia Areata Competitive Intelligence Analysis

4. Alopecia Areata Market Overview at a Glance

5. Alopecia Areata Disease Background and Overview

6. Alopecia Areata Patient Journey

7. Alopecia Areata Epidemiology and Patient Population

8. Alopecia Areata Treatment Algorithm, Current Treatment, and Medical Practices

9. Alopecia Areata Unmet Needs

10. Key Endpoints of Alopecia Areata Treatment

11. Alopecia Areata Marketed Products

12. Alopecia Areata Emerging Therapies

13. Alopecia Areata Seven Major Market Analysis

14. Attribute Analysis

15. Alopecia Areata Market Outlook (7 major markets)

16. Alopecia Areata Access and Reimbursement Overview

17. KOL Views on the Alopecia Areata Market

18. Alopecia Areata Market Drivers

19. Alopecia Areata Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alopecia Areata Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight

Acute Coronary Syndrome Drugs Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Acute Coronary Syndrome Drugs Market”
Acute coronary syndrome companies such as Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others.

(Albany, USA) DelveInsight’s Acute Coronary Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, acute coronary syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

The acute coronary syndrome market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the acute coronary syndrome market.

 

Request for sample report @ Acute Coronary Syndrome Market Insights

 

Key Takeaways from the Acute Coronary Syndrome Market Report

  • Acute coronary syndrome (ACS) comprises acute myocardial infarction and Unstable Angina together. The total incidence cases of ACS in the 7MM were 2.1 million in 2023, of which the highest incidence cases of this disease were in the United States.
  • There are approximately 800,000 incident cases of Acute Myocardial Infarction (AMI) in the US. These AMI cases contribute to approximately 60% cases of total ACS cases in the US.
  • Almost 75% of ACS patients are males.
  • According to DelveInsight’s analysis, the market size for acute coronary syndrome was found to be USD 2.6 billion in the 7MM in 2023.
  • Out of all the emerging therapies for ACS, Novo Nordisk’s Ziltivekimab, Idorsia Pharma/Viatris’ Selatogrel, and CellProthera/BioCardia’s ProtheraCytes are anticipated to generate the maximum revenue by 2034.
  • The other promising acute coronary syndrome therapies in the pipeline include Selatogrel (ACT-246475), Dutogliptin, FARXIGA/FORXIGA (dapagliflozin), FDY-5301, Dalcetrapib (RO4607381), Vicagrel, Zalunfiban (RUC 4), Ziltivekimab, Milvexian, ProtheraCytes, KAND567, Olpasiran (AMG 890), Orticumab, and others.
  • The majority of the high- and mid-stage emerging therapies are small molecules, followed by monoclonal antibodies, stem cell therapy, and small interfering RNA (siRNA).
  • Leading acute coronary syndrome companies such as Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others are developing novel acute coronary syndrome drugs that can be available in the acute coronary syndrome market in the coming years.
  • As reported in April 2024, the EMPACT-MI trial found that JARDIANCE (empagliflozin) did not significantly reduce the composite risk of all-cause mortality and heart failure hospitalization in patients with AMI at increased risk of heart failure when compared to a placebo.
  • In February 2024, CSL announced top-line results from the Phase III AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following AMI. The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112.

 

Discover which therapies are expected to grab the major acute coronary syndrome market share @ Acute Coronary Syndrome Market Report

 

Acute Coronary Syndrome Overview

Acute coronary syndrome (ACS) is a term used to describe a range of conditions resulting from the sudden reduction or interruption of blood flow to the heart. This condition is often caused by the rupture of an atherosclerotic plaque in the coronary arteries, leading to blood clot formation and subsequent blockage. The primary causes of ACS include atherosclerosis, thrombosis, and spasm of the coronary arteries. Risk factors include hypertension, high cholesterol, smoking, diabetes, and a sedentary lifestyle.

The symptoms of ACS can range from mild to severe and typically include chest pain or discomfort, shortness of breath, sweating, nausea, and dizziness. The chest pain is often described as a squeezing or pressure-like sensation. In more severe cases, such as a heart attack (myocardial infarction), symptoms can include radiating pain to the left arm, jaw, or back.

Diagnosis of ACS is based on clinical presentation, electrocardiogram (ECG) findings, and blood tests for cardiac biomarkers such as troponins, which are proteins released into the blood when the heart muscle is damaged. Imaging techniques, including coronary angiography, may be employed to visualize the extent of the blockage and determine the appropriate treatment, which could range from medication to invasive procedures like angioplasty or coronary artery bypass grafting (CABG). Early detection and treatment are crucial in improving outcomes for patients with ACS.

 

Acute Coronary Syndrome Epidemiology Segmentation

The acute coronary syndrome epidemiology section provides insights into the historical and current acute coronary syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The acute coronary syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Incident Cases of ACS
  • Type-specific Incidence of ACS
  • Type-specific Incidence of AMI
  • Gender-specific Incidence of ACS
  • Treated cases of ACS

 

Acute Coronary Syndrome Treatment Market

The initial treatment for all cases of ACS includes aspirin (300 mg), a heparin bolus, and an intravenous heparin infusion, provided there are no contraindications. Antiplatelet therapy with either ticagrelor or clopidogrel is also recommended, with the choice depending on the cardiologist’s preference. Ticagrelor is not administered to patients receiving thrombolysis. Supportive care, such as pain relief with morphine or fentanyl and oxygen for hypoxia, should be provided as needed. Sublingual or intravenous nitroglycerin may also be used for pain relief. In cases of inferior wall ischemia, nitroglycerin can cause significant hypotension and should be used cautiously. Continuous cardiac monitoring for arrhythmias is necessary.

Further treatment depends on whether the condition is STEMI, NSTEMI, or unstable angina. The American Heart Association recommends urgent catheterization and percutaneous intervention for STEMI, with a door-to-procedure time of under 90 minutes. If percutaneous intervention is not available or the patient cannot be transferred to the catheterization lab in under 120 minutes, thrombolytics (such as tenecteplase) are advised. The AHA guidelines suggest the door-to-needle (TNK or other thrombolytic) time should be under 30 minutes.

With the FDA approval of AGEPHA Pharma’s LODOCO, patients with persistent inflammatory risk now have access to a treatment specifically designed to lower the risk of cardiovascular disease. LODOCO works by targeting the inflammatory pathways that contribute to major cardiac events. The current treatment market is divided into various therapeutic classes, including antiplatelet agents, anticoagulants, vasodilators, beta blockers, lipid-lowering drugs, ACE inhibitors, angiotensin-II receptor blockers (ARBs), and calcium channel blockers.

 

To know more about acute coronary syndrome treatment guidelines, visit @ Acute Coronary Syndrome Management

 

Acute Coronary Syndrome Pipeline Therapies and Key Companies

  • Selatogrel (ACT-246475): Idorsia Pharmaceuticals and Viatris
  • Dutogliptin: Recardio
  • FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
  • FDY-5301: Faraday Pharmaceuticals
  • Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche
  • Vicagrel: Jiangsu Vcare PharmaTech
  • Zalunfiban (RUC 4): CeleCor Therapeutics
  • Ziltivekimab: Novo Nordisk
  • Milvexian: Bristol Myers Squibb and Johnson & Johnson Innovative Medicine
  • ProtheraCytes: CellProthera and BioCardia
  • KAND567: Kancera
  • Olpasiran (AMG 890): Amgen and Arrowhead Pharmaceuticals
  • Orticumab: Abcentra

 

Discover more about acute coronary syndrome drugs in development @ Acute Coronary Syndrome Clinical Trials

 

Acute Coronary Syndrome Market Dynamics

The acute coronary syndrome market dynamics are expected to change in the coming years. The ACS market is primarily driven by the increasing prevalence of cardiovascular diseases, rising geriatric populations, and growing awareness of heart health. The expanding global burden of risk factors such as hypertension, diabetes, smoking, and obesity contributes significantly to the incidence of ACS. Technological advancements in diagnostic tools, such as high-sensitivity troponin assays and coronary imaging techniques, have improved early detection and intervention, driving market growth.

Additionally, the development of novel therapeutic agents, including anti-platelet therapies, thrombolytics, and advanced biologics, are further fueling the ACS treatment market. Healthcare infrastructure improvements, along with rising healthcare expenditure in emerging markets, also play a crucial role in expanding access to ACS care. Furthermore, ongoing research in personalized medicine and the adoption of minimally invasive procedures are enhancing the overall treatment landscape, providing a strong boost to market dynamics.

Furthermore, potential therapies are being investigated for the treatment of acute coronary syndrome, and it is safe to predict that the treatment space will significantly impact the acute coronary syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies and devices with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the acute coronary syndrome market in the 7MM.

However several factors may impede the growth of the acute coronary syndrome market. One of the primary challenges is the high cost of treatment, including advanced therapies such as percutaneous coronary interventions (PCI) and novel drug-based therapies. These treatments are often expensive, limiting access in both developing and developed markets. Additionally, the complexity of diagnosing ACS early and accurately remains a challenge, with many patients presenting with non-specific symptoms, leading to delays in treatment and potential complications.

Regulatory hurdles also present barriers, as obtaining approvals for new drugs and devices can be time-consuming and costly. The market is further constrained by the presence of well-established therapies and the difficulty of demonstrating the clinical superiority of new treatments. Lastly, patient adherence to prescribed therapies, lifestyle changes, and the need for long-term management strategies complicate treatment outcomes, adding to the burden of ACS.

 

Scope of the Acute Coronary Syndrome Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
  • Acute Coronary Syndrome Market CAGR: 7.7 %
  • Acute Coronary Syndrome Market Size in 2023: USD 2.6 Billion (7MM)
  • Key Acute Coronary Syndrome Companies: Agepha Pharma, Amgen, Merck, Regeneron and Sanofi, Genentech, Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others
  • Key Approved and Emerging Acute Coronary Syndrome Therapies: LODOCO (colchicine), REPATHA, ZONTIVITY, PRALUENT, Vicagrel, Selatogrel (ACT-246475), Dutogliptin, FARXIGA/FORXIGA (dapagliflozin), FDY-5301, Dalcetrapib (RO4607381), Zalunfiban (RUC 4), Ziltivekimab, Milvexian, ProtheraCytes, KAND567, Olpasiran (AMG 890), Orticumab, and others
  • Therapeutic Assessment: Acute Coronary Syndrome current marketed and emerging therapies
  • Acute Coronary Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Acute Coronary Syndrome Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Acute Coronary Syndrome Market Access and Reimbursement

 

Download the report to understand which factors are driving acute coronary syndrome market trends @ Acute Coronary Syndrome Market Trends

 

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Acute Coronary Syndrome Market Overview at a Glance

4.1. Acute Coronary Syndrome Market Share Distribution by Therapies (%) in 2020 in the 7MM

4.2. Acute Coronary Syndrome Market Share Distribution by Therapies (%) in 2034 in the 7MM

5. Acute Coronary Syndrome Epidemiology and Market Forecast Methodology

6. Key Events

7. Disease Background and Overview

8. Acute Coronary Syndrome Treatment and Management

9. Epidemiology and Patient Population of Acute Coronary Syndrome in the 7MM

10. Acute Coronary Syndrome Patient Journey

11. Marketed Acute Coronary Syndrome Drugs

12. Other Marketed Assets

13. Emerging Acute Coronary Syndrome Therapies

14. Acute Coronary Syndrome Market: 7MM Analysis

15. Acute Coronary Syndrome Unmet Needs

16. Acute Coronary Syndrome SWOT Analysis

17. Acute Coronary Syndrome KOL Views

18. Acute Coronary Syndrome Market Access and Reimbursement

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Coronary Syndrome Drugs Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight